Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.

Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.

Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology

CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.

Webinar presenter Jeffrey Gregg, MD, University of Nevada

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.

Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs

CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Manage Subscription

To receive CAP TODAY magazine, please subscribe here.
For change of address, mail new information to: CAP TODAY Circulation, 325 Waukegan Road, Northfield, IL 60093-2750 or visit here.

Industry News

Helmer Scientific launches next-gen cell washer

March 2, 2018—Helmer Scientific has announced the release of its FDA 510(k)-cleared, next-generation automatic cell washing system, the UltraCW II, for hospital blood banks and clinical laboratories. The UltraCW II automates steps within typical tube testing blood bank workflows. It removes plasma and unwanted antibodies from blood cells for pretransfusion testing procedures—ABO and Rh grouping, antibody identification, and cross-matching. The system features a color touchscreen for intuitive and easy-to-use programming and operation. An electronic flow meter and digital calibration ensure

CDC to use IGRAs for immigration TB screening

Feb. 28, 2018—The U.S. Centers for Disease Control and Prevention issued a notification to U.S. civil surgeons stating it will require the use of FDA-approved interferon gamma release assays for tuberculosis screening. The CDC plans for the change to go into effect Oct. 1. The use of the tuberculin skin test will no longer be allowed for use in immigration screening, including for children under age five. Qiagen said in a statement that it welcomes the decision by the CDC to use

Respiratory bacterial panel gets CE-IVD mark

Feb. 28, 2018—ElitechGroup Molecular Diagnostics launched its Respiratory Bacterial Elite MGB Panel, a high-performance multiplex assay for the diagnosis of bacterial respiratory infections and validated with the Elite InGenius fully automated sample-to-result system. The panel detects and differentiates in a single reaction M. pneumoniae, C. pneumoniae, and L. pneumophila. A clinical study has demonstrated a performance of 100 percent diagnostic sensitivity and 100 percent diagnostic specificity for all targets. “We are proud to extend the Elite InGenius respiratory menu, which now

FDA clears QuickVue Influenza A+B test

Feb. 27, 2018—Quidel announced it has received FDA 510(k) clearance for its CLIA-waived QuickVue Influenza A+B assay. The assay allows for the rapid, qualitative detection of influenza type A and type B antigens directly in nasal swab and nasopharyngeal swab specimens from symptomatic patients in approximately 10 minutes. In a clinical study, the QuickVue Influenza A+B test was shown to meet the FDA’s reclassification criteria for class II rapid influenza diagnostic tests. More top news

FDA clears Sebia Hydrashift 2/4 daratumumab assay

Feb. 26, 2018—Sebia announced it has received FDA 510(k) clearance for its Hydrashift 2/4 daratumumab assay, intended to be used with Hydragel IF, for the qualitative detection of monoclonal proteins in human serum by immunofixation electrophoresis. This in vitro diagnostic reagent mitigates the daratumumab-mediated interference seen in immunofixation results for patients with multiple myeloma treated with Darzalex (daratumumab), a fully human monoclonal antibody that binds to CD38. The assay was developed in collaboration with Janssen Biotech to provide the clinical

CAP TODAY webinar on influenza testing

Feb. 22, 2018—CAP TODAY is hosting a webinar titled “Diagnostic Accuracy of Novel and Traditional Rapid Tests for Influenza Compared with Reverse Transcriptase PCR” on Tuesday, Feb. 27, 1 PM ET. Presented by Jesse Papenburg, MD, MSc, FRCPC, and moderated by CAP TODAY publisher Bob McGonnagle, this hourlong webinar will empower you to understand new approaches to influenza testing and technologies, discover the key points of evaluation, and gain insight into the current field. Dr. Papenburg, FRQS clinical research scholar

Qiagen to buy Stat-Dx

Feb. 20, 2018—Qiagen has entered into an agreement to acquire Stat-Dx, a developer of molecular diagnostics systems, for $147 million. Once the transaction is completed, which is expected later this year, Qiagen will launch the QIAstat-Dx system, a next-generation, fully integrated multiplex platform for syndromic disease testing. QIAstat-Dx enables scalable sample-to-insight processing of up to 48 molecular targets simultaneously and can provide qualitative and quantitative insights in about one hour. The system, which is based on DiagCore technology, uses single-use

Qiagen launches Therascreen PITX2 test in Europe

Feb. 14, 2018—Qiagen announced the European launch of its novel Therascreen PITX2 RGQ PCR Kit, a clinically validated DNA methylation assay that helps predict the response of certain high-risk breast cancer patients to anthracycline-based chemotherapy. The CE-IVD marked assay is Qiagen’s first epigenetic test in breast cancer. “We are very pleased to introduce this important test for personalized health care used to assess the best treatment approach for high-risk breast cancer patients. This reliable, clinically validated assay determines the PITX2

Inspirata buys digital pathology company Omnyx

Feb. 13, 2018—Inspirata, a biotechnology and software company, announced it has acquired Pittsburgh-based Omnyx from GE Healthcare. Omnyx’s flagship digital pathology software, Dynamyx, aims to enhance the pathology workflow by providing new channels for collaboration and tools to boost efficiency. The software is CE-marked in Europe and licensed by Health Canada for in vitro diagnostic use. “The acquisition of Omnyx positions Inspirata with the most comprehensive digital pathology workflow solution in the world,” Satish Sanan, CEO of Inspirata, said in

MARKETPLACE

TRENDING